APL Diagnosis: How This Leukemia Is Confirmed

Acute promyelocytic leukemia (APL) is confirmed through a layered diagnostic process that combines microscopic examination of blood and bone marrow, flow cytometry, and genetic testing to detect a specific chromosomal rearrangement found in virtually every case of the disease. That rearrangement, a swap of material between chromosomes 15 and 17, produces a fusion gene called PML-RARα that both drives the leukemia and makes it uniquely treatable. Because APL can cause fatal bleeding within hours or days of presentation, the diagnostic workup operates under unusual time pressure, with rapid tests sometimes running in parallel rather than in sequence.

Why Diagnosis Is an Emergency

APL stands apart from other leukemias because most patients already have a dangerous clotting disorder at the time they show up in a hospital. The abnormal promyelocytes release substances that trigger widespread, uncontrolled activation of the clotting system, which paradoxically leads to both clot formation and severe bleeding. Hemorrhage remains a major cause of early death, and some patients die before treatment can begin.¹ This reality shapes the entire diagnostic approach: clinicians do not wait for every test to come back before starting targeted therapy. If the microscope and initial labs strongly suggest APL, treatment with all-trans retinoic acid (ATRA) typically begins immediately while confirmatory genetic results are still pending.

The hemorrhagic and thrombotic complications remain a significant barrier to better outcomes even in the modern treatment era.² That is why a fast, reliable diagnostic pipeline matters so much. The goal is not just accuracy but speed.

What the Microscope Shows

The first clue usually comes from looking at cells under a microscope. In the classic, or “hypergranular,” form of APL, the abnormal promyelocytes are packed with large, dark-staining granules and often contain bundles of needle-like structures called Auer rods. These cells look distinctive enough that an experienced hematologist can suspect APL within minutes of reviewing a blood smear or bone marrow aspirate. Morphology alone can point toward the specific diagnosis of APL even before any genetic test is run, especially when characteristic features are present.³

The trouble is that not every case looks classic. A variant called the microgranular form accounts for a meaningful minority of APL cases. Instead of the obvious heavy granulation, the abnormal cells have fine, barely visible granules and can closely resemble the blasts seen in other types of acute leukemia. Microgranular APL tends to present with higher white blood cell counts and can be harder to recognize on a smear. In one reported case, a child with the microgranular variant presented with fever and nosebleeds, and the blood count showed extreme leukocytosis with the majority of cells being atypical promyelocytes.⁴ Relying on morphology alone would miss or delay recognition of such cases, which is why additional layers of testing exist.

Flow Cytometry Narrows the Field

Flow cytometry is a technique that passes individual cells through a laser beam and measures the proteins on their surface and inside them. Each type of leukemia has a different fingerprint of surface markers, and APL’s fingerprint is distinctive. The typical APL cell is positive for CD13, CD33, and CD117, and negative for HLA-DR and CD34. It also shows high side scatter, a measurement that reflects internal complexity, in this case the heavy granule content of the promyelocytes.⁵

The absence of HLA-DR is particularly useful. Most other types of acute myeloid leukemia express this marker, so its absence in a cell population that is otherwise myeloid helps single out APL quickly. A multi-center study found that combining specific patterns of CD64, CD13, CD33, myeloperoxidase positivity, and high side scatter could distinguish APL from other acute myeloid leukemia subtypes with close to perfect sensitivity and specificity.⁶

Even the microgranular variant shares this immunophenotypic profile. One study comparing the two subtypes found that their surface marker patterns were essentially indistinguishable, including the characteristic absence of HLA-DR.⁷ That means flow cytometry can catch cases that the microscope might struggle with. However, flow cytometry results are suggestive, not definitive. The gold standard for confirmation is genetic.

It is worth noting that APL cells do not all look the same on flow cytometry. Research has identified at least four distinct patterns based on how the cells plot on standard scatter graphs. One pattern, characterized by low side scatter and positivity for CD34, resembles the blast gate used for other leukemias and can be misleading if clinicians are not looking for it.⁸ Awareness of these atypical patterns prevents flow cytometry from becoming a false source of reassurance.

The Genetic Hallmark

What truly defines APL at a biological level is a reciprocal translocation between the long arms of chromosomes 15 and 17. In plain terms, a piece of chromosome 15 swaps places with a piece of chromosome 17. This rearrangement is seen in virtually every patient with APL and in no other type of cancer.⁹ Identifying this translocation, written as t(15;17), is the single most important step in confirming the diagnosis.

The translocation fuses two genes: PML on chromosome 15 and RARα (retinoic acid receptor alpha) on chromosome 17. The resulting PML-RARα fusion protein jams the normal process by which immature blood cells mature into functioning white blood cells, trapping them at the promyelocyte stage. Understanding the fusion gene was crucial not just for diagnosis but for explaining why ATRA and arsenic trioxide work as treatments: they directly target the fusion protein and release the maturation block.¹⁰

Conventional cytogenetics, where lab technicians grow the leukemia cells and photograph their chromosomes, can detect t(15;17) and remains a standard part of the diagnostic workup. But it takes days to get a result because the cells need time to divide in culture. A faster genetic approach is fluorescence in situ hybridization (FISH), which uses fluorescent probes that bind to specific stretches of DNA on chromosomes 15 and 17. FISH can confirm the rearrangement within 24 hours in most cases and is the frontline genetic test in many centers.

Rapid Tests That Buy Hours

Given the time pressure, laboratories have developed methods to get a preliminary genetic answer even faster than FISH. One of the most practical is PML immunofluorescence staining. Instead of looking at DNA, this test looks at the PML protein inside cells. In normal cells, the PML protein forms a handful of bright, discrete dots in the nucleus. When the PML-RARα fusion protein is present, this organized pattern breaks apart into a scattered, dusty, or “microgranular” pattern of many tiny specks. Reading this pattern under a fluorescence microscope takes an experienced eye, but the entire test can be completed in under four hours.¹¹

This approach is especially valuable in hospitals that do not have on-site molecular genetics labs. The anti-PML antibody test is technically simple, inexpensive, and requires only a small tissue sample. In a study of 110 genetically confirmed APL patients, 108 showed the disrupted PML pattern, giving the test very high sensitivity.¹² While it still needs to be followed by formal molecular testing to fully characterize the fusion, it gives clinicians enough confidence to start ATRA within the same day the patient presents.

Coagulation Markers as a Diagnostic Shortcut

Lab work measuring clotting function can also point toward APL before genetic results arrive. Because APL’s coagulopathy is so severe and so characteristic, certain clotting markers run at levels rarely seen in other leukemias. D-dimer, a breakdown product of blood clots, is particularly telling. One study found that D-dimer levels at or above a specific high threshold were a sensitive and moderately specific indicator of APL when used to distinguish it from other acute leukemias.¹³

Compared to other acute myeloid leukemia subtypes that also present with clotting problems, APL patients tend to have much higher fibrin degradation products and D-dimer levels alongside much lower fibrinogen and lower white blood cell counts.¹⁴ This combination of a severe coagulopathy with relatively low white cells is a red flag that should immediately prompt suspicion of APL and trigger the rapid diagnostic pathway.

When the Standard Tests Come Back Negative

In rare instances, APL can hide from the usual detection methods. Roughly fewer than one percent of APL cases are what geneticists call “cryptically” rearranged, meaning the translocation is structured in a way that conventional chromosome analysis and even standard FISH probes cannot detect it.¹⁵ In such cases, the chromosomes look normal under the microscope, and the FISH probes designed to find the PML-RARα fusion do not light up. Yet the patient clearly has the disease based on everything else: the morphology, the immunophenotype, the coagulopathy.

These cryptic cases require alternative molecular approaches. Reverse transcription polymerase chain reaction (RT-PCR), which detects the PML-RARα messenger RNA transcript directly, can catch fusions that FISH misses because it is looking at the gene product rather than the chromosomal structure. Real-time quantitative RT-PCR has high sensitivity and good reproducibility for detecting the fusion transcript.¹⁶ More recently, next-generation sequencing panels have proven capable of identifying the fusion even in cryptic cases, sometimes returning a result within about 48 hours of sample arrival.¹⁵

Variant translocations represent a different kind of diagnostic challenge. Instead of fusing with PML, the RARα gene on chromosome 17 occasionally fuses with a different partner gene entirely. One such partner, STAT5B, creates a fusion that looks like APL under the microscope but does not respond to ATRA, the standard targeted therapy. In a reported case, the standard PML-RARα FISH probe came back negative, but a RARA break-apart probe revealed an atypical rearrangement, and next-generation sequencing identified STAT5B as the fusion partner.¹⁷ This matters enormously for treatment: if the variant is ATRA-insensitive and the lab only tested for the standard PML-RARα fusion, the patient would be prescribed a drug that will not work.

Risk Stratification at Diagnosis

Once APL is confirmed, the next step is figuring out how dangerous the individual case is likely to be. The most widely used risk factor is the white blood cell count at presentation. Patients with a count above ten billion per liter are classified as high risk and are more prone to the hemorrhagic syndrome that makes APL so dangerous in its early days.¹⁸ High-risk patients receive more intensive treatment upfront.

Some researchers have argued that white blood cell count alone does not capture the full picture. One group proposed a scoring system that adds platelet count and hemoglobin level to the equation, reasoning that patients who are both severely anemic and have very low platelets at presentation have worse outcomes even if their white cell count is not dramatically elevated. In their retrospective analysis, this combined score outperformed the standard risk model at predicting remission rates, overall survival, and early death.¹⁹ Whether this expanded scoring system will become standard practice remains an open question, but it illustrates that the diagnostic blood work does double duty: confirming the disease and gauging how aggressively to treat it.

Tracking the Fusion Gene After Treatment

Diagnosis does not end once treatment begins. Because APL has such high cure rates with modern therapy, the focus shifts to detecting any leftover disease, known as minimal residual disease (MRD). The same PML-RARα fusion transcript that confirms the initial diagnosis becomes the molecular target for long-term monitoring. Labs use quantitative RT-PCR to measure how many copies of the transcript remain in blood or bone marrow samples over time.

Most patients in remission still carry detectable levels of the PML-RARα transcript, even years after treatment. The key is not whether the transcript is present but whether it is rising. In one study, patients who relapsed showed dramatically increased transcript levels in samples taken two to four months before their clinical relapse became apparent. Older, less sensitive testing methods gave negative results on the same samples, meaning they would have missed the warning entirely.²⁰

A large prospective study confirmed that MRD monitoring was far more powerful at predicting relapse than any initial clinical variable, including the white blood cell count that guides upfront risk stratification. When patients whose molecular tests signaled an impending relapse were treated pre-emptively with arsenic trioxide, the majority avoided full-blown clinical relapse. Using this strategy, the overall clinical relapse rate dropped to about five percent at three years.²¹ MRD monitoring has essentially turned the diagnostic fusion gene into a long-term surveillance tool.

When APL Appears Outside the Bone Marrow

In a small number of cases, APL cells show up in places beyond the bone marrow and blood. The central nervous system is one such site, and when leukemia cells infiltrate the fluid surrounding the brain and spinal cord, the prognosis worsens. Predicting which patients will develop central nervous system involvement at the time of relapse is difficult, and the diagnosis typically requires sampling of spinal fluid and examining it for abnormal cells.²² This is not part of the routine initial workup for most patients but becomes relevant if neurological symptoms develop or if the disease returns after initial treatment.

The diagnostic tools for extramedullary APL are largely extensions of the same ones used for the bone marrow: morphology of cells found in the affected tissue or fluid, flow cytometry on those cells, and molecular testing for the PML-RARα transcript. The challenge is that cell counts in spinal fluid are often low, making each of these tests less reliable than when performed on a bone marrow sample with millions of cells available. Clinicians sometimes have to piece together a diagnosis from incomplete results across multiple test types rather than getting a clean confirmation from any single one.

How Each Test Fits Into the Timeline

In practice, the diagnostic workup for APL unfolds in overlapping waves rather than a neat sequence. Here is roughly how the timeline plays out from the moment a doctor suspects the diagnosis:

Hour zero: The blood smear and basic clotting labs raise suspicion. If morphology and coagulation findings are consistent with APL, ATRA is typically started immediately.
Within hours: Flow cytometry results arrive and either strengthen or weaken the suspicion. PML immunofluorescence staining, where available, can provide a preliminary genetic confirmation in under four hours.
Within one to two days: FISH results confirm or rule out the t(15;17) translocation in most cases. RT-PCR testing for the PML-RARα transcript may also be underway.
Within one to two weeks: Conventional cytogenetics return a full chromosomal picture, sometimes revealing additional abnormalities alongside the t(15;17). This rarely changes immediate management but contributes to the complete diagnostic record.

The entire process is designed around the principle that a delay in starting ATRA can cost lives. Clinicians accept some diagnostic uncertainty in the first hours and refine the picture as confirmatory results filter in. A false start on ATRA in a patient who turns out not to have APL is a manageable problem. A missed or delayed diagnosis in someone who does have it can be fatal.